TLPH earnings analysis
What we found in TLPH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text does not include the financial statements needed to assess quarterly revenue, margins, EPS, balance-sheet movements, operating cash flow, free cash flow, or capex. The principal financial signal is severe liquidity pressure: the company says current capital may not fund operations for the next 12 months and expects significant losses in 2026. Clinical execution, regulatory approval, single-source manufacturing, tariffs, and potential tax-attribute limitations remain material headwinds.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remain effective
- Under Item 4, management concluded that disclosure controls were effective at the reasonable-assurance level, and stated that there had been no changes during the period that materially affected internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern and liquidity risk
- The filing states that, based on current operating expenses, existing capital is not expected to fund operations for the next 12 months if additional financing is unsuccessful. It also expects significant losses in 2026, creating substantial doubt about going-concern status.
- Tax attribute limitations
- The company states that an issuance of common stock totaling over 50% on September 10, 2025 triggered an ownership change, limiting its net operating losses and tax credits under Sections 382 and 383 and potentially increasing future tax liabilities.
- Tariff and single-source supply risk
- The filing adds material international trade exposure: the active ingredient for Niyad is manufactured in Japan and Niyad is manufactured in China, while tariffs and trade restrictions may increase development costs and disrupt supply. The company also states that its nafamostat-based product candidates currently rely on a single source for active ingredient and finished product.
What they said about what is next.
No quantitative revenue or EPS outlook is provided in the extracted 10-Q text. The filing states that the company expects significant losses in 2026 and that current capital is not expected to fund operations for the next 12 months if additional capital cannot be raised.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Talphera, Inc. reported improved financials for Q1 2026, with a loss of $2.6 million (or $0.04 per share), an improvement in EPS from a loss of $0.10 in Q1 2025, while revenues were absent as anticipated. With cash and…
- 10-K · March 23, 2026
- Talphera’s 10-K emphasizes a concentrated strategy: develop, obtain FDA approval for, and commercialize Niyad (nafamostat) as the first FDA‑approved regional anticoagulant for CRRT, while deprioritizing some pre-filled…
- 10-Q · August 14, 2025
- Talphera reported Q2 2025 GAAP net loss of $3,489,000 (‑$0.10 per share), an improvement versus Q2 2024 net loss of $3,827,000 (‑$0.15). Cash and cash equivalents declined to $6,791,000 as of June 30, 2025 from…
- 10-Q · November 13, 2024
- Talphera reported Q3 revenue of $0 (Q3 2023: $117) and GAAP loss per share of $(0.13) (Q3 2023: $(0.08)), with operating loss widening to $(3,749)k from $(3,309)k. Cash improved to $11,117k as of September 30, 2024…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TLPH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever